These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 16515983

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Hormonal predictors of prostate cancer.
    Sofikerim M, Eskicorapci S, Oruç O, Ozen H.
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.
    Reeves JR, Dulude H, Panchal C, Daigneault L, Ramnani DM.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6018-22. PubMed ID: 17062675
    [Abstract] [Full Text] [Related]

  • 6. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
    Imasato Y, Xuan JW, Sakai H, Izawa JI, Saito Y, Chin JL, Moussa M.
    J Urol; 2000 Nov 15; 164(5):1819-24. PubMed ID: 11025776
    [Abstract] [Full Text] [Related]

  • 7. Histological diagnosis of prostate cancer in Korean men aged 70-79 years.
    Shim HB, Lee SE, Park HK, Ku JH.
    Jpn J Clin Oncol; 2007 Oct 15; 37(10):782-7. PubMed ID: 17913831
    [Abstract] [Full Text] [Related]

  • 8. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.
    Cancer; 2007 Apr 15; 109(8):1689-95. PubMed ID: 17330856
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC, Chen MH, Renshaw AA, Loffredo M, Sussman B, D'Amico AV.
    Urology; 2007 Mar 15; 69(3):515-9. PubMed ID: 17382156
    [Abstract] [Full Text] [Related]

  • 11. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb 15; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 12. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
    Wetter A, Ajdukovic AN, Fliessbach K, Lehnert T, Engl T, Jacobi V, Vogl TJ.
    Rofo; 2006 Apr 15; 178(4):385-90. PubMed ID: 16607587
    [Abstract] [Full Text] [Related]

  • 13. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D.
    Clin Cancer Res; 2006 Aug 15; 12(16):4872-5. PubMed ID: 16914574
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource.
    Datta MW, Dhir R, Dobbin K, Bosland MC, Melamed J, Becich MJ, Orenstein JM, Kajdacsy-Balla AA, Patel A, Macias V, Berman JJ.
    J Urol; 2005 May 15; 173(5):1546-51. PubMed ID: 15821483
    [Abstract] [Full Text] [Related]

  • 17. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
    Schatzl G, Marberger M, Remzi M, Grösser P, Unterlechner J, Haidinger G, Zidek T, Preyer M, Micksche M, Gsur A.
    Urology; 2005 Jun 15; 65(6):1141-5. PubMed ID: 15893813
    [Abstract] [Full Text] [Related]

  • 18. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L, Egevad L, Ekman P, Hellström M.
    Scand J Urol Nephrol; 2007 Jun 15; 41(4):302-7. PubMed ID: 17763221
    [Abstract] [Full Text] [Related]

  • 19. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz PI.
    Cancer; 2008 Nov 15; 113(10):2695-703. PubMed ID: 18853417
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.